Skip to main content

Table 1 Demographics and baseline characteristics

From: Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry

 

Total n = 100

GE n = 50

GL n = 50

p-value

Age (Years)

44 ± 11

41 ± 10

47 ± 10

0.004

Male/Female

63/37

29/21

34/16

0.300

SOFA

6 ± 4

5.93 ± 4.65

6.10 ± 3.56

0.807

BMI (kg/m2)

34.4 ± 6.3

35.4 ± 6.0

33.4 ± 6.5

0.121

Hypertension, n (%)

38 (38)

21 (42)

17 (34)

0.410

Diabetes, n (%)

25 (25)

10 (20)

15 (30)

0.248

Other comorbidities, n (%)

19 (19)

24 (48)

14 (28)

0.039

Lactate (mmol/L)

2.2 [1.2–2.5]

2.5 [0.9–3.1]

2.0 [1.2–2.38]

0.401

PaO2/FiO2 (mmHg)

73 [62–154]

73 [59–128]

81 [62–170]

0.595

PaCO2 (mmHg)

52 [46–62]

48 [41–54]

56 [46–67]

0.115

PEEP (cm H2O)

14 [10–15]

16 [14–16]

12 [10–14]

0.027

Ppeak (cm H2O)

29 [25–35]

37 [29–39]

28 [25–31]

0.011

Driving pressure (cm H2O)

14 [10–18]

23 [21–25]

12 [9–18]

0.030

D-Dimer (mcg/mL)

2.11 [1.29–5.57] (n = 26)

2.01 [1.51–3.97] (n = 12)

4.51 [1.25–78] (n = 14)

0.368

CRP (mg/dL)

11.60 [4.25–23.40] (n = 32)

13.1 [9.5–20.3] (n = 9)

8.7 [3.2–26.9] (n = 23)

0.4892

Ferritin (ng/mL)

1132 [618–2592] (n = 26)

1339 [631–1927] (n = 10)

1061 [405–2768] (n = 16)

0.712

MV before ECMO (h)

19.5 [7–43]

16 [5–25]

39 [12–87]

0.001

MV before HA (h)

25 [13–79]

16 [5–29]

79 [21–146]

 < 0.001

ECMO before HA (h)

0 [0–5]

0 [0–1]

1 [0–78]

 < 0.001

ICU admission to ECMO (h)

58 [35–138]

37 [17–41]

138 [87–231]

 < 0.001

ICU admission to HA (h)

86 [38–186]

38 [19–42]

186 [119–304]

 < 0.001

  1. Data are presented as n (%), median [interquartile range] or mean ± standard deviation as appropriate